PA
MDGL icon

Profund Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Profund Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Sell
2,850
-2,012
-41% -$1.03M 0.04% 264
2026
Q1 		$2.55M Buy
4,862
+705
+17% +$337K 0.09% 148
2025
Q4 		$2.42M Sell
4,157
-45
-1% -$23K 0.07% 176
2025
Q3 		$1.93M Sell
4,202
-988
-19% -$369K 0.06% 199
2025
Q2 		$1.57M Sell
5,190
-1,063
-17% -$317K 0.06% 221
2025
Q1 		$2.07M Sell
6,253
-231
-4% -$75.9K 0.09% 171
2024
Q4 		$2M Sell
6,484
-2,323
-26% -$653K 0.07% 184
2024
Q3 		$1.87M Buy
8,807
+1,991
+29% +$509K 0.07% 198
2024
Q2 		$1.91M Buy
6,816
+1,053
+18% +$251K 0.07% 185
2024
Q1 		$1.54M Sell
5,763
-1,397
-20% -$329K 0.06% 220
2023
Q4 		$1.66M Sell
7,160
-563
-7% -$98.5K 0.07% 212
2023
Q3 		$1.13M Buy
7,723
+1,898
+33% +$357K 0.06% 261
2023
Q2 		$1.35M Buy
5,825
+459
+9% +$124K 0.07% 244
2023
Q1 		$1.3M Buy
5,366
+4,233
+374% +$1.15M 0.08% 227
2022
Q4 		$329K Buy
+1,133
New +$111K 0.02% 592
2019
Q1 		– Sell
-1,829
Closed -$206K – 1225
2018
Q4 		$206K Buy
1,829
+67
+4% +$10.4K 0.01% 1014
2018
Q3 		$377K Buy
+1,762
New +$442K 0.01% 1026

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Profund Advisors's MDGL Position: Q2 2026 in Review

Profund Advisors reduced its Madrigal Pharmaceuticals (MDGL) stake by 41% in Q2 2026, selling an estimated $1.03M and leaving 2,850 shares worth $1.53M. The position accounts for 0.04% of the portfolio, ranked #264.

Profund Advisors first reported a position in MDGL in Q3 2018 and has held it in 17 quarters since. The position peaked at $2.55M in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Profund Advisors held 2,850 shares of Madrigal Pharmaceuticals worth $1.53M as of Q2 2026.
  • Profund Advisors sold 2,012 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $1.03M.
  • Madrigal Pharmaceuticals made up 0.04% of Profund Advisors's portfolio in Q2 2026, its #264 holding.
  • Profund Advisors first reported a position in Madrigal Pharmaceuticals in Q3 2018 and has held it in 17 quarters since.
  • Profund Advisors's Madrigal Pharmaceuticals position peaked at $2.55M in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.